title: Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients.
authors.forename: B
authors.initials: B
authors.lastname: Byl
authors.forename: D
authors.initials: D
authors.lastname: Baran
authors.forename: F
authors.initials: F
authors.lastname: Jacobs
authors.forename: A
authors.initials: A
authors.lastname: Herschuelz
authors.forename: J P
authors.initials: JP
authors.lastname: Thys
mesh_terms: D000293:Adolescent; D000328:Adult; D000583:Amikacin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D002442:Ceftazidime / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D002511:Cephalosporins / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000382:microbiology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D013183:Sputum / Q000378:metabolism / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000583:Amikacin; D002442:Ceftazidime